Fundz

Vevo Therapeutics Launches With Oversubscribed $12M Seed Financing To Discover Better Drugs Using Higher Resolution In Vivo Data Generated At Scale

PRIVATEDec 08, 2022

Amount Raised

$12 Million

Round Type

Seed

San FranciscoBiotechnologyArtificial IntelligenceMachine Learning

Investors

Camford CapitalAIX VenturesMubadala CapitalWing Venture Capital

Description

Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, launched today with an oversubscribed and upsized $12M seed financing round. Wing Venture Capital and General Catalyst co-led the round with participation from Mubadala Capital, AIX Ventures, and Camford Capital.

Quick answer

Vevo Therapeutics raised $12 Million in a Seed round, dated December 8, 2022. Investors: Camford Capital, AIX Ventures, Mubadala Capital and Wing Venture Capital. Vevo Therapeutics is based in San Francisco, California, United States.

How much did Vevo Therapeutics raise?
Vevo Therapeutics raised $12 Million in a Seed round on December 8, 2022.
Who invested in Vevo Therapeutics?
Camford Capital, AIX Ventures, Mubadala Capital and Wing Venture Capital are named as investors in this round.
What does Vevo Therapeutics do?
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients.
Where is Vevo Therapeutics based and how big is it?
Vevo Therapeutics is based in San Francisco, California, United States.

Source: Fundz verified event record.

Who else raised in Biotechnology and Artificial Intelligence around the same time

Companies in the same sectors as Vevo Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Rocket One raised $10M on January 3, 2023.
  • RegASK raised $10M (Series A) on December 15, 2022.
  • In-Med Prognostics raised $2.1M (Seed) on December 12, 2022.
  • Sonde Health raised $19M (Series B) on December 8, 2022.
  • Biorelate raised $7.8M (Funding Round) on November 29, 2022.
  • Turbine raised $20M (Series A) on November 22, 2022.

Who to call at Vevo Therapeutics, and when

A new round usually means Vevo Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Vevo Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Vevo Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Vevo Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Vevo Therapeutics

Location

San Francisco, California, United States

About

Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Vevo Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Vevo Therapeutics's next move

See what Strategic adds

Vevo Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.